Biotech Values

[go seek]

IDIX perhaps... but pls show me where in the the last 6 months, management said a successful interaction study means an automatic move to Phase 3 with NM283...

Also the data reported was on a treatable basis as per study design protocol and the PR stated this.

I too am disappointed that IDIX moved down... and it was because of the delay.

Idenix has a lot of positives...
as you know Idenix is not paying for the trials, so they must clear all development w/ Novartis.

The trial met the endpoints for which it was designed.

Best wishes
long IDIX